A
Ashwin Gollerkeri
Researcher at Pfizer
Publications - 32
Citations - 1724
Ashwin Gollerkeri is an academic researcher from Pfizer. The author has contributed to research in topics: Binimetinib & Cetuximab. The author has an hindex of 14, co-authored 32 publications receiving 949 citations.
Papers
More filters
Journal ArticleDOI
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Scott Kopetz,Axel Grothey,Rona Yaeger,Eric Van Cutsem,Jayesh Desai,Takayuki Yoshino,Harpreet Wasan,Fortunato Ciardiello,Fotios Loupakis,Yong Sang Hong,Neeltje Steeghs,Tormod Kyrre Guren,Hendrik Tobias Arkenau,Pilar García-Alfonso,Per Pfeiffer,Sergey Orlov,Sara Lonardi,Elena Elez,Tae Won Kim,Jan H.M. Schellens,Christina Guo,Asha Krishnan,Jeroen Dekervel,Van Morris,Aitana Calvo Ferrándiz,Line Schmidt Tarpgaard,Michael Braun,Ashwin Gollerkeri,Christopher Hunt Keir,Kati Maharry,Michael D Pickard,Janna Christy-Bittel,Lisa Anderson,Victor Sandor,Josep Tabernero +34 more
TL;DR: A combination of encorafenib, cetuximab, and binimetinib resulted in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with the BRAF V600E mutation.
Journal ArticleDOI
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.
Josep Tabernero,Axel Grothey,Eric Van Cutsem,Rona Yaeger,Harpreet Wasan,Takayuki Yoshino,Jayesh Desai,Fortunato Ciardiello,Fotios Loupakis,Yong Sang Hong,Neeltje Steeghs,Tormod Kyrre Guren,Hendrik Tobias Arkenau,Pilar García-Alfonso,Elena Elez,Ashwin Gollerkeri,K. Maharry,Janna Christy-Bittel,Scott Kopetz +18 more
TL;DR: PURPOSEBEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators' choice of irinotecan or FOLFIRI plus CetuxIMB in patients with BRAFV600E-mutant metastatic...
Journal ArticleDOI
Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study
Eric Van Cutsem,Sanne Huijberts,Axel Grothey,Rona Yaeger,Pieter Jan Cuyle,Elena Elez,Marwan Fakih,C. Montagut,Marc Peeters,Takayuki Yoshino,Harpreet Wasan,Jayesh Desai,Fortunato Ciardiello,Ashwin Gollerkeri,Janna Christy-Bittel,Kati Maharry,Victor Sandor,Jan H.M. Schellens,Scott Kopetz,Josep Tabernero +19 more
TL;DR: In the safety lead-in, the safety and tolerability of the encorafenib, binimetinib, and cetuximab regimen is manageable and acceptable for initiation of the randomized portion of the BEACON Colorectal Cancer trial.
Journal ArticleDOI
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Paolo A. Ascierto,Reinhard Dummer,Helen Gogas,Keith T. Flaherty,Ana Arance,Mario Mandalà,Gabriella Liszkay,Claus Garbe,Dirk Schadendorf,Ivana Krajsová,Ralf Gutzmer,Jan Willem B. de Groot,Carmen Loquai,Ashwin Gollerkeri,Michael D Pickard,Caroline Robert +15 more
TL;DR: The COLUMBUS trial as mentioned in this paper showed that COMBO450 decreased the risk of death by 39% (hazard ratio [HR], 0.61; 95% CI, 0.48-0.79).
Journal ArticleDOI
A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer.
Josep M. del Campo,Michael J. Birrer,Craig Davis,Keiichi Fujiwara,Ashwin Gollerkeri,Martin Gore,Brett E. Houk,Susie Lau,Andres Poveda,Antonio González-Martín,Carolyn Y. Muller,Kei Muro,Kristen J. Pierce,Mie Suzuki,Jennifer Vermette,Amit M. Oza +15 more
TL;DR: Gedatolisib administered by weekly intravenous infusion demonstrated acceptable tolerability and moderate activity in patients with recurrent endometrial cancer following platinum-containing chemotherapy.